Fate Therapeutics (FATE) Income towards Parent Company (2012 - 2026)

Fate Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at -$147.7 million for Q1 2026.

• Quarterly Income towards Parent Company rose 12.01% year-over-year to -$147.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$300.5 million (up 69.45% YoY) and the FY2025 annual result came in at -$524.7 million, up 5.48% from the prior year.
• Income towards Parent Company was -$147.7 million for Q1 2026 at Fate Therapeutics, down from -$32.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$32.5 million in Q4 2025 and bottomed at -$420.0 million in Q4 2024.
• A 5-year average of -$179.6 million and a median of -$155.3 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 110.33% — and 2025, when it soared 92.26%.
• Fate Therapeutics' Income towards Parent Company stood at -$357.8 million in 2022, then dropped by 2.75% to -$367.6 million in 2023, then declined by 14.24% to -$420.0 million in 2024, then surged by 92.26% to -$32.5 million in 2025, then slumped by 354.5% to -$147.7 million in 2026.
• Business Quant data shows FATE's Income towards Parent Company at -$147.7 million in Q1 2026, -$32.5 million in Q4 2025, and -$75.3 million in Q3 2025.